Munich (ots/PRNewswire) - World Thrombosis Day Interactive Infographic [http://af-vte.thisinfographic.com/wtd ] Daiichi Sankyo is proud to partner with World Thrombosis Day [http://www.worldthrombosisday.org ] to promote vital global awareness of thrombosis, its causes, risk factors, and signs and symptoms. ...
Tokyo (ots/PRNewswire) - The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help prevent stroke and systemic embolism (SE) in patients suffering from the heart rhythm disorder atrial fibrillation (AF).[1] ...
Tokyo (ots/PRNewswire) - The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has today recommended a new treatment to help patients suffering from blood clots in the legs and lungs.[1] Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) ...
Munich (ots/PRNewswire) - FOR EU MEDIA ONLY. NOT FOR UK MEDIA. - Daiichi Sankyo announces enrollment of first patient in ETNA-AF-Europe and the commencement of ETNA-VTE-Europe, two regional registries to collect robust information on how once-daily LIXIANA(R) is being used in real world settings - ETNA is a Daiichi Sankyo global initiative which will collect data ...
Tokyo (ots/PRNewswire) - Press release not intended for US and UK media - EU approval paves the way for LIXIANA(R) (edoxaban) to be made available across all European member states - Marketing authorisation is based on data from the ENGAGE AF-TIMI 48 and Hokusai-VTE studies, the largest single comparative global ...
Brussels (ots/PRNewswire) - Report[1] recommendations aim to improve management of AF as numbers expected to double from 8.8 to 17.9 million adults aged over 55 years between 2010 and 2060[2] Launched in Brussels today at the start of Heart Rhythm Week (1-7 June 2015) the Future of Anticoagulation Report[1] ...
Tokyo (ots/PRNewswire) - - The European Committee for Medicinal Products for Human Use recommended approval of once-daily Lixiana(R) - The positive opinion is based on data from the ENGAGE AF-TIMI 48 and Hokusai-VTE studies, the largest single comparative global trials of a novel oral anticoagulant in patients with ...
Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana(R) (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism (SE) in ...
Munich (ots/PRNewswire) - - Survey findings show that 97% of European cardiologists believe that non-valvular atrial fibrillation (NVAF) patients experience a delay in diagnosis,[1] which is associated with a higher risk of stroke[2] - European Cardiologists reveal the importance of reviewing patient ...
Barcelona, Spain (ots/PRNewswire) - Registry provides new insights into AF treatment decisions, including patients' quality of life and treatment satisfaction[1],[2] (Photo: http://photos.prnewswire.com/prnh/20140902/703596 ) ESC Congress 2014, 02 September 2014, Barcelona, Spain: Daiichi Sankyo today announced one ...
Barcelona, Spain (ots/PRNewswire) - Registry provides new insights into AF treatment decisions, including patients' quality of life and treatment satisfaction[1],[2] (Photo: http://photos.prnewswire.com/prnh/20140902/703596 ) ESC Congress 2014, 02 September 2014, Barcelona, Spain: Daiichi Sankyo today announced one ...
Munich, Germany (ots/PRNewswire) - For European Media Only, Not for UK Media Atrial fibrillation (AF) is the most common heart rhythm disorder[1] resulting in a five-fold increased risk of stroke compared with the general population[2] Daiichi Sankyo today announced its commitment to extend the PREvention oF ...
Ehra Europace 2013, Athens, Greece (ots/PRNewswire) - [For European Media Only, Not for UK Media] Baseline data from The PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF) highlights advances and existent gaps in current management of thromboembolic events in people with AF Daiichi Sankyo Europe GmbH today announced the first ...
München (ots) - New data from the SEVITENSION study show the fixed-dose combination treatment Sevikar® (olmesartan/amlodipine) to be superior to perindopril in combination with amlodipine in reducing central blood pressure When the traditional arm (brachial) method of measurement is used, blood pressure is usually found to be higher than it is in the large central ...
Munich, Germany (ots) - * Lack of patient adherence to hypertension treatment is one of the root causes of failure to reach blood pressure goals, contributing to increased risk of serious cardiovascular events * The Daiichi Sankyo myHypertensionCare patient support programme aims to improve patient engagement and ...
Munich (ots/PRNewswire) - The registry plans to gather data from more than 4,000 patients with VTE across seven European countries, providing insights into the clinical management of a disease that is a leading cause of morbidity and mortality[1] Daiichi Sankyo Europe GmbH announced the enrolment of the first ...
Munich (ots) - Jan Van Ruymbeke, 53, will become the new Chief Executive Officer of Daiichi Sankyo Europe this autumn. The native of Belgium will replace Reinhard Bauer, who is retiring after 10 years in this position. Van Ruymbeke will assume responsibility for the pharmaceutical company in October. Until the end ...
Munich (ots/PRNewswire) - **Not be used by UK media** To mark this year's World Hypertension Day, Daiichi Sankyo Europe has announced a website for patients offering more information about hypertension management and treatment. http://www.hypertensioncare.eu is now available to patients and physicians across Europe ...
Munich (ots/PRNewswire) - - For European Media Only -- Collection of real life data from 5,000 atrial fibrillation patients (AF) across seven countries will generate invaluable insights into one of Europe's leading causes of stroke(1,2) -- Daiichi Sankyo Europe GmbH today announced the enrolment of the first patient ...
Munich (ots/PRNewswire) - Pooled results of the STARS E-III and STARS J-V studies presented at the 2011 American Society of Hematology (ASH) Annual Meeting Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the results of a pooled analysis showing that edoxaban*, a direct oral once-daily ...
Tokyo (ots/PRNewswire) - -- First Direct Oral Factor Xa Inhibitor Available to Japanese Patients -- Building on its cardiovascular portfolio, Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), is proud to announce the launch of LIXIANA(R) (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban) in Japan. This ...
Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that the company has received its first marketing approval for LIXIANA(R) (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan. Edoxaban, ...
Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited announced that its investigational once-daily oral, direct factor Xa inhibitor, edoxaban, was shown to be superior to enoxaparin sodium in preventing venous thromboembolic (VTE) events in patients following total hip replacement (THR), a type of major ...
Stockholm (ots/PRNewswire) - DAIICHI SANKYO announced today that the ongoing trials ENGAGE AF-TIMI 48 (The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation) and HOKUSAI VTE with their investigational factor Xa inhibitor edoxaban are enrolling in accordance to plan. The ...
Tokyo, July 12, 2010 (ots/PRNewswire) - Daiichi Sankyo Company, Limited announced that its investigational once-daily oral, direct factor Xa inhibitor, edoxaban, was shown to be superior to enoxaparin in preventing venous thromboembolic (VTE) events in patients following total knee replacement (TKR), a type of ...
Munich, June 28, 2010 (ots/PRNewswire) - Interim data from a prospective Investigator Initiated Trial (IIT) presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA(R) (raloxifene 60mg; once-daily, distributed in 34 countries by DAIICHI SANKYO), indicated ...
Tokyo, Japan and Edison, N.J. (ots) - First Patient Randomized and Dosed in New Trial with Factor Xa Inhibitor, Edoxaban Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. ...
Munich, Germany (ots) - An educational programme available on DVD is launched today, on World Osteoporosis Day, bringing together the glamorous world of ballroom dance with the serious nature of disease management. Sponsored by DAIICHI SANKYO EUROPE and endorsed by the International Osteoporosis Foundation, ...
Barcelona (ots) - New treatment could offer further option in addition to current standard of care in thromboembolic disease Edoxaban, an oral factor Xa inhibitor, is currently being investigated in the pivotal phase III study ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor xA next GEneration in ...
Munich (ots) - Product development agreement focused on ARQ 197, c-Met inhibitor, with discovery collaboration directed toward novel kinase inhibitors ArQule, Inc. (NASDAQ: ARQL) and DAIICHI SANKYO Co., Ltd. (TSE: 4568) today announced that they have entered into two agreements that form the ...